Mode
Text Size
Log in / Sign up
Phase 4 N=60 Randomized Triple-blind Treatment

Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain

Typical Facial Pain · Atypical Facial Pain

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcome: Primary: The Proportion of Subjects Reporting at Least 50% Overall Pain Relief — 19; 14; 10; 16 Participants — p=.196

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Bupivacaine (Drug); Triamcinolone (Drug); Dexamethasone (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Northwestern University
Primary completion
Mar 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
The Proportion of Subjects Reporting at Least 50% Overall Pain Relief
19; 14; 10; 16 .196

Summary

Trigeminal neuralgia is a craniofacial pain syndrome that is typically characterized by unilateral severe, recurrent, electrical pain in one or more distributions of the trigeminal nerve. Current treatment strategies include oral medications as first line therapy with surgical interventions reserved for those patients who are refractory to medications or unable to tolerate medication side effects. Despite these current treatment options, many patients continue to have symptoms. Ultrasound-guided trigeminal nerve block allows for fine adjustment of the needle tip and direct observation of the medicine. Local anesthetic and steroids have been successfully used for diagnostic and or therapeutic nerve pain with great success. Steroids can be short or long acting in duration with varying side effects. If there exists a difference in duration of action, using the longer acting drug will provide a greater period of symptom relief for the patient and may allow the patient to undergo fewer interventional procedures.

Eligibility Criteria

Inclusion Criteria

  • All patients presenting to the Northwestern Pain Center who are eligible and scheduled to receive a ultrasound-guided trigeminal nerve block.

Exclusion Criteria

  • Exclusion is the same for patients who are not eligible for ultrasound guided nerve blocks.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02024724). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search